Alyeska Investment Group
ETNB

Alyeska Investment Group’s 89bio ETNB Stock Holding History

Alyeska Investment Group’s Portfolio ETNB Stock Details ETNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-150,000
Closed -$1.75M – 597
2024
Q1 		$1.75M Hold
150,000
– – 0.01% 383
2023
Q4 		$1.68M Hold
150,000
– – 0.01% 383
2023
Q3 		$2.32M Hold
150,000
– – 0.02% 381
2023
Q2 		$2.84M Hold
150,000
– – 0.02% 384
2023
Q1 		$2.28M Buy
+150,000
New +$1.96M 0.02% 344
2022
Q3 		– Sell
-150,000
Closed -$483K – 412
2022
Q2 		$483K Buy
+150,000
New +$453K 0.01% 531

Other funds holding ETNB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alyeska Investment Group's ETNB Position: Q3 2025 in Review

Alyeska Investment Group sold out of 89bio (ETNB) in Q3 2025, closing a stake of 576,973 shares — an estimated $5.67M sold.

Alyeska Investment Group first reported a position in ETNB in Q4 2019 and held it in 17 quarters. The position peaked at $7.24M in Q4 2024. 198 funds tracked by Wall St. Rank hold ETNB as of Q3 2025.

  • Alyeska Investment Group reported no remaining 89bio position as of Q3 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 576,973 89bio shares in Q3 2025, an estimated $5.67M.
  • Alyeska Investment Group first reported a position in 89bio in Q4 2019 and held it in 17 quarters.
  • Alyeska Investment Group's 89bio position peaked at $7.24M in Q4 2024.
  • 198 funds tracked by Wall St. Rank held 89bio as of Q3 2025.

Based on Alyeska Investment Group's 13F filing for Q3 2025, filed 17 Nov 2025.